MedStar Georgetown University Hospital, first in Washington Metropolitan Area to offer promising investigational treatment for COVID-19
Researchers are optimistic as hospital’s first convalescent plasma recipient is discharged
May 20, 2020
Featured in :
Emergency medicine/trauma , Medical Education , MedStar in the community , Primary care , Research ,Explore By Category :
- Blood Management
- Cancer
- Cardiology
- Emergency medicine/trauma
- Endocrinology
- Gastroenterology/digestive diseases
- Healthcare industry
- Innovation
- Interventional Pulmonology
- Interventional Radiology
- Medical Education
- MedStar in the community
- Neurosciences
- Nursing
- Oncology
- Orthopaedics and sports medicine
- Orthopedic
- Pediatrics
- Primary care
- Quality and Patient Safety
- Rehabilitation
- Research
- Stem Cell Transplant and Cellular Immunotherapy
- Technology/IT
- Transplant
- Transplantation
- Women’s services
- Video Gallery
- MedStar Washington Hospital Center News
- MedStar Harbor Hospital News
- MedStar Good Samaritan Hospital News
- MedStar Franklin Square Medical Center News
- MedStar Union Memorial Hospital News
- MedStar Montgomery Medical Center News
- MedStar St. Mary's Hospital News
- MedStar Health System News
- MedStar Southern Maryland Hospital Center News
WASHINGTON — MedStar Georgetown University Hospital, the first hospital in the Washington, D.C. Metropolitan Area to offer convalescent plasma therapy, has discharged its first patient who received the investigational treatment.
While there is no proven treatment for this virus, researchers are optimistic that the antibodies in convalescent plasma, a component of blood, collected from individuals who have recovered from COVID-19, can lead to more positive outcomes.
Anecdotal evidence suggests that a patient’s ability to recover is due, in part, to the existence of antibodies in blood that are capable of fighting viruses that cause illness. While use of convalescent plasma for COVID-19 was just recently approved by the FDA for clinical trials and expanded clinical use, the use of convalescent plasma has been successful in the past for treating diseases like hepatitis B, influenza and Ebola.
Patrick Bright, the first patient to receive convalescent plasma at MedStar Georgetown was discharged on May 2 after spending 3 weeks in the hospital. Before receiving the convalescent plasma, Bright was in the ICU where doctors told him and his family that they were not optimistic about his recovery from acute COVID-19 infection.
Despite the bleak prognosis, Bright was determined to fight. He recalls lying in his hospital bed, holding his fist up like a boxer and telling his family, who were on a video call, “I’m a fighter. I’m not going anywhere.” Today he credits his recovery to getting convalescent plasma. “I was on a ventilator for five days and I started turning around after getting the convalescent plasma. My doctors told me the plasma therapy was a crucial part of my recovery.”
MedStar Georgetown has treated more than 30 COVID-19 patients with convalescent plasma and is encouraging more people to donate. Anyone who has recovered from COVID-19 and has been symptom free for 14 days can be considered to donate plasma and help save the lives of severely ill patients like Patrick Bright.
Bright and his wife, who also had COVID-19, are eager to donate their plasma in the future to help other people recover.
Interested donors who meet the outlined criteria should email their name and phone number to [email protected] for pre-screening and directions on where to donate. Your single plasma donation may be used to treat up to three other COVID-19 infected patients who need your help.
Media Contacts
Debbie Asrate
Director of Media Relations
Office: 703-558-1287
[email protected]
or
Nicole Vowell
Media Specialist
Office: 703-558-1593
Cell: 801-919-4251
[email protected]
Category : Emergency medicine/trauma , Medical Education , MedStar in the community , Primary care , Research ,
Back to Top
Related News

MedStar Georgetown University Hospital receives 5th Beacon Award for Excellence from American Association of Critical-Care Nurses
Category : Emergency medicine/trauma , Quality and Patient Safety ,

National Cancer Institute Renews Prestigious Designation of Georgetown Lombardi Comprehensive Cancer Center
Category : Cancer , Oncology , Research ,